Despite the novelty of these new 1,4-dihydropyridine Sirt3 activators, the lack of animal model testing demonstrates the current superiority of ADTL-SA1215 as the Sirt3 activator of choice for probing the roles of Sirt3 in cancer. This evidence concerns the gene SIRT3 and cancer.